Pharmaceutical companies hold a lot of power and influence, but they don’t always get things right. If you’ve been harmed by a drug, taking legal action can be a way to make things better for yourself and future patients.
When people sue drug makers, it can lead to better testing of medications. This means future patients might be less likely to be harmed by these drugs. Lawsuits often result in new rules to protect consumers.
Did you diagnosed with a retinal vasculitis or retinal vascular occlusion after using Beovu for macular degeneration? Get the guidance from an experienced lawyer to help with a Beovu lawsuit.
Need Quality Medical Record Reviews?
What is Beovu Injection?
Beovu is an injection used to treat two persistent eye diseases. One is wet age-related macular degeneration (AMD) and the other is diabetic macular edema (DME). AMD is a common cause of vision loss in people over 50, and DME is a major cause of vision problems for those with diabetes.
Beovu is an injection-only drug produced by Swiss company Novartis. The FDA authorized Beovu (brolucizumab dbll – Beovu generic name) on October 7, 2019. Just nine months after the FDA approval, some patients experienced a rare and severe eye inflammation.
As a result, many people have sued Novartis, claiming the company did not properly investigate or inform users about the potential risks of Beovu, including the possibility of long-term eye damage.
Can Adderall cause retinal detachment? Yes, some people experienced retinal detachment, blurred vision, and vision problems after taking Adderall.
What Injuries are Connected to Beovu?
Serious Beovu side effects may cause rapid vision changes or may take several days to manifest. These significant visual changes can sometimes be painful, but they can sometimes be painless. The following are the most common beovu injection side effects:
- Blurred vision
- Cataracts
- Difficulty Distinguishing Colors
- Vitreous floaters
- Eye pain
- Conjunctival hemorrhage
- Inflammation of the retinal blood vessels
- Increased eye pressure
- a possible danger of heart attack, stroke, or blood clots
- Retinal hemorrhage
- Vitreous detachment
- Conjunctivitis
Beovu, like any medication, can cause side effects. In two clinical studies, blurred vision was the most common issue, affecting 10% of participants.
The company claims that serious side effects occur in less than 10% of people, but these issues have worried both patients and doctors. Some serious problems include vision loss, retinal vasculitis, retinal vein blockage, and retinal detachment.
You must talk to your doctor if you think you’re experiencing side effects from Beovu, especially if they affect your eyes.
Legal Claims Regarding Potential Risks
In February 2020, the American Society of Retina Specialists (ASRS) warned its members about Beovu and its connection to eye inflammation.
Just five months after Beovu was approved, the ASRS conducted a safety study to see if the drug increased the risk of a serious eye condition called occlusive retinal vasculitis. They found 11 cases of this condition in people using Beovu, leading to 14 cases of eye injury. These findings raised concerns about the drug, as it seemed to increase the risk of severe vision loss.
On June 11, 2020, the FDA updated Beovu’s warning label to highlight the risk of retinal vasculitis and retinal vascular occlusion following injections. Doctors were advised to tell patients to report any changes in their vision immediately.
In Nebraska, a woman sued Beovu’s manufacturer, Novartis, claiming that the drug caused her severe eye problems. The plaintiff claims that because her doctor believed Beovu to be a safe and effective treatment for her wet AMD, she was given a prescription for it.
She experienced severe eye problems as a result of her Beovu eye injection, such as central retinal artery occlusion, a blood flow obstruction to the retina of the eye that can result in a rapid loss of vision. Her lawsuit against Beovu asks for a variety of damages, including general damages, special damages, punitive damages, exemplary damages, and court expenses.
Beovu lawsuits allege that the drug’s maker neglected to inform patients and medical professionals about possible harmful eye effects. A case for damages may be filed by those who used Beovu and had vision loss, retinal vasculitis, occlusive retinal vasculitis, or other visual issues.
Are you one among the victims? Pursue a lawsuit to get deserving reparation.
Trust our expertise for a winning claims
Hurry up to grab free trial worth $500.
Beovu Drug Label Safety Review by Novartis
Following receipt of the ASRS reports of vasculitis and concurrent occlusion, Novartis declared that they would conduct a detailed investigation into the reported cases, commissioning both an external safety review of Beovu and internal research into the side effects reported by the ASRS. 3.3% of the study participants suffered from retinal vasculitis, and 2.1% additionally had a vascular occlusion, according to the external safety review.
The pharmaceutical company declared that “there is a confirmed safety signal of rare risk factors of retinal vasculitis and retinal vascular occlusion that may lead to severe vision damage.” The company then submitted an application to the FDA for permission to add warnings about these potential side effects to the product’s packaging.
On June 9, 2020, the FDA approved Novartis’s revision of Beovu’s product labeling, adding a new warning concerning the dangers of retinal vasculitis and retinal vascular occlusion. Before June 2020, when the FDA issued additional warnings concerning blindness and visual loss, more than 50,000 patients had gotten Beovu injections.
Has Beovu Ever Been Recalled?
No. Beovu recall has not been issued; however, in 2020, the FDA authorized label changes involving adverse eye concerns to better notify consumers and medical professionals.
A Novartis safety study conducted in 2020 showed predisposing variables for Beovu eye issues, such as past intraocular inflammation or retinal vascular blockage, within 12 months of the initial injection treatment.
Even though the risk rate for Beovu eye issues was 0.46% for all patients, those who had the mentioned diseases before treatment had a 3.97% risk rate for Beovu complications. Novartis modified Beovu safety profile and contraindications to reflect these hazards.
Due to the discovery of Beovu’s connection to ocular inflammation and other issues, Novartis abruptly terminated two more safety trials in May 2021 after disclosing one year’s worth of findings from a Phase III study.
The trials examined the safety and effectiveness of more frequent dosages for Beovu patients. Although the FDA has not yet declared a Beovu recall, the revised label revisions adequately inform patients and physicians of the drug’s hazards.
Beovu Lawsuit 2022 Update
Barbara Frye, who received a Beovu injection in January 2020, filed a lawsuit after being diagnosed with retinal vascular occlusion in March 2020, attributing it to Beovu. Novartis updated the Beovu warning label in June 2020 after maintaining low rates of Beovu-induced eye inflammation.
Novartis argued FDA approval preempted state failure-to-warn claims in response to Frye’s lawsuit.
A federal court in Arkansas rejected an attempt by Novartis to have a Beovu vision injury claim dismissed based on federal preemption. Federal preemption usually causes product liability claims based on a failure to warn to be rejected.
After the judge denied Novartis’ motion to dismiss, the Beovu lawsuits regarding the eye injury were given the green light to proceed.
There is no central MDL, and coordinated pretrial procedures have not been formally created, even though common facts and legal difficulties have been raised in Beovu litigation against Novartis throughout the federal court system. As a result, Beovu lawsuits are ongoing before numerous federal courts in multiple U.S. District Courts around the country.
As cases progress and Beovu trials are planned, they will be closely observed by the Beovu attorneys engaged in the action. They might affect any ultimate Beovu settlement agreements that may be negotiated to prevent a jury from considering each claim in the ensuing years.
Beovu Lawsuit Update 2023
In March 2023, Frye filed a Stipulation of Dismissal with Prejudice, concluding her case amid trial rescheduling and the judge’s denial of Novartis’ dismissal motion in September 2022.
Beovu Lawsuit Update 2024
No trials or court-sanctioned settlements have taken place in the Beovu lawsuits.
Value of the Beovu Vision Loss Lawsuit Settlement
Beovu lawsuits for blindness and visual loss are just beginning to be brought against Novartis. Therefore, it is undoubtedly premature to extrapolate the possible Beovu lawsuit settlements value of the Beovu visual loss lawsuit by comparing it to payouts in previous cases involving identical injuries if this action is successful.
In the Beovu lawsuits, each plaintiff will ask for compensation for some degree of eyesight loss or damage. Some will claim to be completely blind, while others will claim to have partial vision loss.
The amount of past and future medical expenditures, whether the plaintiff had an income loss or a loss of earning ability, and the degree of the plaintiff’s pain and suffering all play a role in how much Beovu lawsuits are valued. For instance, someone blind would probably be given more considerable vision loss compensation for their pain and suffering than someone who only lost half of their vision.
Reasons to Bring Beovu Lawsuits
A spate of Beovu lawsuits against Novartis is anticipated following these events. Anyone who took Beovu injections and later suffered from visual problems, blindness, or other adverse effects may be able to sue Novartis. Possible Beovu-related injuries and responses include
- Retinal vasculitis
- Retinal vascular occlusion
- Inflammation of the retina
- Vision loss
After getting injections of the Beovu medication, if you or a loved one had any of the adverse reactions noted above, you may be eligible to file a Beovu vision loss class action lawsuit against Novartis.
More than 70,000 patients used Beovu from its approval in October 2019 to its update warnings in June 2020. All of those patients were unaware of the possible risks and hazards associated with the medicine, as they ought to have been. Patients may be eligible for financial compensation if they trusted the maker and now have damaged eyes.
It’s challenging to bring a Beovu macular degeneration lawsuit against a large multinational pharmaceutical business, but knowledgeable Beovu lawyers have the skills and resources to fight for you. Consumers who have been injured by dangerous products, such as Beovu, are protected by product liability lawsuits.
What Are the Forms of Compensation Available to Beovu Victims?
Drug companies may and should be held accountable for how their products impact patients’ health, happiness, and capacity to make a livelihood when they cause harm to patients through unsafe or deficient medications.
Given that Beovu has been connected to lifelong blindness, a disabling condition that has an impact on many facets of life, sufferers may be entitled to substantial Beovu settlements, including:
- All costs associated with treating the drug damage, including any ongoing care
- Compensation for lost wages
- Physical and mental anguish brought on by the injury
- Any eyeglasses or other aids you may need to improve your eyesight
- Future earning potential loss or reduction if your eyesight loss prohibits you from working
All these losses are regarded as compensatory damages, which means they’re intended to compensate for the suffering you’ve endured.
A lawsuit must be brought against a pharmaceutical company within certain time limitations. The patient’s bad eye condition was discovered to have been caused by Beovu use at some point. Therefore, that instant serves as a starting point for the time ranges.
Make a top-notch medical record review company to review your medical records.
Decode complex records for your lawsuit advantage
The critical pieces of evidence in the Beovu lawsuits will be a complete ophthalmological examination and the patient’s medical history. LezDo TechMed can help you in the important process of reviewing your medical records. Every significant medical occurrence that alters the course of a case is highlighted in LezDo TechMed’s Medical Narrative Summary Review.
To wrap up,
Beovu is still on the market despite warnings about possible eye injuries. Pharmaceutical firms are responsible for thoroughly evaluating their products and notifying the public of any known harmful effects. Novartis continues to support the medication as a safe and successful therapy for wet AMD. However, patients with existing eye inflammation might still be at risk.
Visit our Instagram, to get more insights:
View this post on Instagram
